

**REMARKS**

Claims 56-64, 66, 68-75, 77, 79-82, 84, and 86-89 are currently pending in this application upon entry of this paper. Claims 1-55, 65, 67, 76, 78, 83, 85, and 90-119 have been cancelled without prejudice. Applicants reserve the right to file one or more continuation, divisional, or continuation-in-part applications directed to any canceled subject matter. Claims 56-58 have been amended to more clearly recite the claimed invention. Specifically, claims 56-58 have been amended to incorporate the features recited in claim 65 with the exception of anthracycline compounds. Applicants have removed this subject matter to place the claims in condition for allowance and reserve the right to pursue it in a later application. Support for the amendments can be found in the application as-filed. No new matter has been added by the amendments.

**I. The Rejections Under 35 U.S.C. § 102(a)**

Claims 56-61, 64, 65, 69-73, 76, 80-82 and 87-89 are rejected on pages 3-4 of the office action under 35 U.S.C. 102(a) as allegedly anticipated by Udagawa *et al.* (JP 08217787) (“Udagawa”). In particular, the office action alleges that Udagawa discloses the fat-soluble derivatives of anthracycline glycosides for use as anticancer agents.

Applicants respectfully submit that the claims as amended are not anticipated by the disclosure of Udagawa. Specifically, the claims as amended do not include anthracycline compounds or derivatives thereof.


Applicants respectfully submit that the claims are in condition for allowance and request that the rejection of claims 56-61, 64, 69-73, 80-82 and 87-89 under 35 U.S.C. 102(a) as allegedly anticipated by Udagawa be reconsidered and withdrawn.

**II. Conclusions**

Should the Examiner disagree with any of the above arguments, Applicants respectfully request a telephone interview with the Examiner and undersigned attorney for Applicants to advance the prosecution of the application.

Except for issue fees payable under 37 C.F.R. § 1.18, the Commissioner is hereby authorized by this paper to charge any necessary fees during the entire pendency of this application including fees due under 37 C.F.R. §§ 1.16 and 1.17, which may be required, including any required extension of time fees, or credit any overpayment to Deposit Account 50-0310. This paragraph is intended to be a Constructive Petition for Extension of Time in accordance with 37 C.F.R. § 1.136(a)(3).

Respectfully submitted,



Dean L. Fanelli (Reg. No. 48,907)

Date: July 25, 2008

**MORGAN, LEWIS & BOCKIUS LLP**

**Customer No.: 009629**

1111 Pennsylvania Avenue, N.W.

Washington, D.C. 20004

(202) 739-3000-phone

(202) 739-3001-fax